Delving into the Latest Updates on Withania somnifera Extract with Synapse

Overview

Basic Info

Drug Type

Herbal medicine

Synonyms

Withania somnifera roots extract

Target

SLC8A3

Mechanism

SLC8A3 agonists(solute carrier family 8 member A3 agonists)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic DiseaseOther Diseases

Active Indication

Amyotrophic Lateral SclerosisAlzheimer Disease

Inactive Indication

Generalized anxiety disorderSchizophrenia

Originator Organization-

Active Organization

Huazhong University of Science & Technology

WellSpring School of Allied Health

Sunnybrook Health Sciences Centre

Inactive Organization

University of California, Los Angeles

Natreon, Inc.

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

To determine whether a standardized extract of Withania somnifera will reduce psychopathology scores (PANSS total score) in persons with schizophrenia. A secondary aim is to determine whether WSE reduces measures of positive and negative symptoms (PANSS subscales) and stress scores on the Perceived Stress Scale (PSS).

Start Date01 Dec 2018

Sponsor / Collaborator

University of Maryland

[+1]

100 Clinical Results associated with Withania somnifera Extract

Login to view more data

100 Translational Medicine associated with Withania somnifera Extract

Login to view more data

100 Patents (Medical) associated with Withania somnifera Extract

Login to view more data

6

Literatures (Medical) associated with Withania somnifera Extract

01 Nov 2024·Human Psychopharmacology: Clinical and Experimental

Safety and efficacy of Withania somnifera for anxiety and insomnia: Systematic review and meta‐analysis

Review

Author: Raza, Ghana ; Waseem, Areesha ; Fatima, Kaneez ; Muskan, Fariha ; Rashid, Ahmed Mustafa ; Shaikh, Yasmeen ; Khan, Umeed ; Shahid, Hiba ; Zaheer, Muhammad Kashan ; Malik, Javeria ; Jaffery, Syeda Fatima

AbstractObjectiveDespite the historical neurological use of Withania somnifera, limited evidence supports its efficacy for conditions like anxiety and insomnia. Given its known anti‐stress properties, this review evaluated its safety and efficacy for anxiety and insomnia.MethodsWe searched Medline, Cochrane Library, and Google Scholar until August 2023 for randomized controlled trials (RCTs) comparing W. somnifera to placebo in patients with anxiety and/or insomnia. Outcome measures included changes in anxiety levels via the Hamilton Anxiety Scale (HAM‐A), Sleep Onset Latency (SOL), Total Sleep Time (TST), Wake After Sleep Onset (WASO), Total Time in Bed (TIB), Sleep Efficiency (SE), and Pittsburgh Sleep Quality Index (PSQI) score. We utilized a random‐effect model for pooling Mean Differences (MD) with a 95% Confidence Interval (CI). Heterogeneity was assessed through sensitivity and subgroup analysis, and the quality of RCTs was evaluated using the Cochrane revised risk of bias tool.ResultsPooled results from five RCTs (n = 254) demonstrated that W. somnifera significantly reduced HAM‐A scores (MD = −5.96; [95% CI −10.34, −1.59]; P = 0.008; I2 = 98%), as well as sleep parameters such as SOL, TST, PSQI, and SE, but not WASO and TIB.ConclusionWhile W. somnifera extracts yielded promising results, further research with larger sample sizes is needed to confirm its effects on anxiety and insomnia.

28 Dec 2021·Cureus

Withania somnifera as an Adjunctive Treatment for Refractory Restless Legs Syndrome in Parkinson’s Disease: A Case Report

Author: Chaudhari, Kaustubh S ; Tiwari, Rakesh R ; Singh, Harish B ; Joshi, Swati V ; Chaudhari, Saurabh S

Non-motor symptoms of Parkinson's disease (PD), such as insomnia and restless legs syndrome (RLS), tend to worsen and become refractory as neurodegeneration progresses. We report the case of a 72-year-old female with a six-year history of PD and two-and-half-year history of insomnia and refractory RLS. We added a neuroprotective agent, Withania somnifera, to the existing treatment regimen for her insomnia. Besides the partial remission of her insomnia and motor symptoms of PD, there was a complete reversal of the RLS symptoms. Withania somnifera has been shown to improve PD symptoms by preventing oxidative damage of the nigrostriatal dopaminergic neurons and improving dopamine levels in the midbrain and corpus striatum. Our case provides the first-time evidence where Withania somnifera added for insomnia caused a complete remission of refractory RLS, possibly due to its anti-apoptotic and pro-dopaminergic actions. Withania somnifera could prove beneficial in cases where the disease advances but further addition of dopamine agonists for refractory RLS is not possible due to the risk of dopamine augmentation.

01 Jun 2019·Clinical ImmunologyQ3 · MEDICINE

Effect of Withania somnifer on CD38 expression on CD8+ T lymphocytes among patients of HIV infection

Q3 · MEDICINE

Article

Author: Tyagi, Sonu ; Das, Bimal Kumar ; Singh, Ravinder ; Maurya, Shesh Prakash

CD38 on CD8 + T cells is considered a reliable marker of HIV disease progression. Withania somnifer, a traditional ayurvedic medicine, has Th1 immunomodulatory properties. PBMCs from 38 HIV patients were exposed to Withania somnifer root extract at standardized concentration. An overall decline in the percentage of CD38 expressing CD8 + T lymphocytes was observed, though the statistical significance was varied with different categories of HIV patients. Withania somnifer could have promising impact on HIV disease and therefore warrants a further study on larger parameters.

100 Deals associated with Withania somnifera Extract

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Amyotrophic Lateral Sclerosis	Phase 2	CA	Sunnybrook Health Sciences Centre	19 Oct 2021
Generalized anxiety disorder	Phase 2	IN	Natreon, Inc.	01 Mar 2011
Schizophrenia	Phase 1	US	University of California, Los Angeles	01 Dec 2018
Alzheimer Disease	Preclinical	CN	Huazhong University of Science & Technology	20 Dec 2022
Alzheimer Disease	Preclinical	US	WellSpring School of Allied Health	20 Dec 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03437668 (CTgov)	Phase 2/3	Schizophrenia	47	WSE (Withania Somnifera Extract (WSE))	jvkrifnmwu(rnqqfqxjeq) = fyqythatzd istnqfttsc (tbmdrytpky, uxfrfukhij - ppttyxzvty) View more	-	08 Oct 2024
				Placebo Oral Tablet (Placebo Tablets)	jvkrifnmwu(rnqqfqxjeq) = bpwujxsrco istnqfttsc (tbmdrytpky, fbdxrjijgb - aqupjbnbno) View more